MerusCase - Technology for Attorneys
No more bulky files lying around, and no more having to spend 15 minutes looking for a file: everything we need is easily accessible in Merus. We have used other case management systems, but Merus is …
About Us | Merus
At Merus, we are clinically advancing leading-edge, targeted treatments to address the unmet needs of patients with various types of cancer.
Merus hails 'unprecedented' survival on solid tumor bispecific
May 23, 2025 · Merus’ data set covers 45 patients with PD-L1-positive recurrent or metastatic head and neck squamous cell carcinoma. Participants in the phase 2 trial received petosemtamab and Merck …
Merus CEO: We’re really optimistic about the potential for our ... - CNBC
Jun 5, 2025 · CNBC’s Angelica Peebles sits down with Merus CEO Dr. Bill Lundberg to discuss the company’s recent positive results in head & neck cancer and what he sees for the future of bispecific …
Merus: Riding The Bispecific Wave In Oncology - Seeking Alpha
Apr 7, 2025 · Rather than targeting a single drug candidate, Merus offers an overall value proposition. Its proprietary Biclonics and Multiclonics platforms generate novel bispecific and multispecific...
Merus (MRUS) Stock Price & Overview
Dec 16, 2025 · Get the latest Merus N.V. (MRUS) stock price with news, financials and other important investing information.
Merus N.V. Receives Second FDA Breakthrough Therapy ... - Nasdaq
Feb 18, 2025 · Merus N.V. announced that the U.S. FDA has granted Breakthrough Therapy designation to its drug petosemtamab in combination with pembrolizumab for the first-line treatment …
Merus | Al. Neyer is now Merus, marking growth and a new era.
Jan 21, 2025 · Merus is a nationally recognized, 100% employee-owned design-build development firm specializing in the construction, development, ownership, and management of a diverse real estate …
MerusCase Review: Cost, Features, Pros & Cons (2026) | Lawyerist
MerusCase is customizable, cloud-based law practice management software that’s best for small to medium-sized litigation firms. However, it’s a poor fit for firms looking to integrate third-party services.
Merus Announces Publication of an Abstract on Petosemtamab in …
Apr 14, 2023 · About Merus N.V. Merus is a clinical-stage oncology company developing innovative full-length human bispecific and trispecific antibody therapeutics, referred to as Multiclonics®.